| abstract |
5-Phenylbenzylamine compounds of formula (I-a), their pharmacologically acceptable salts; a process for preparing the same; and intermediates for their preparation are disclosed, wherein: Ra, Rb1, and Rb2 are each hydrogen, halogen, lower alkyl, halogenated lower alkyl, or lower alkoxy; Rc1 is hydrogen, lower alkyl, or acyl; R2c and Re are each hydrogen or lower alkyl; Rd is hydrogen, lower alkyl, or acyl; and Rf is lower alkyl or lower cycloalkyl; and R1, R2 and R3 are as defined in the specification. These compounds are suitable for the treatment of a disease selected from inflammation, allergic disease, pain, migraine headache, neuralgia, itching, cough, central nervous system disease, digestive organs disease, nausea, emesis, urination disorder, circulatory disease and immune disorder. |